- AstraZeneca's TAGRISSO® (osimertinib), combined with chemotherapy, significantly improves overall survival in EGFR-mutated advanced lung cancer.
- The FLAURA2 Phase III trial confirms TAGRISSO's effectiveness as the backbone therapy for EGFRm lung cancer.
- TAGRISSO plus chemotherapy is approved in over 80 countries, enhancing its global reach in lung cancer treatment.
The final overall survival (OS) analysis from the FLAURA2 Phase III trial has demonstrated that AstraZeneca's TAGRISSO (osimertinib) combined with pemetrexed and platinum-based chemotherapy significantly improves overall survival in patients with first-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This positive outcome reinforces the role of TAGRISSO (ticker: AZN) as a vital therapy in EGFRm lung cancer treatment.
Building on interim results, the trial signaled a consistent survival benefit, especially in the first-line advanced setting. Dr. Pasi A. Jänne, principal investigator for the FLAURA2 trial, emphasized the importance of prolonging survival and enhancing the patient experience, stating that these results solidify the use of osimertinib, either alone or with chemotherapy, as a standard of care in advanced EGFRm lung cancer.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D at AstraZeneca, noted that these findings complement extensive evidence supporting TAGRISSO's use in early-stage and advanced disease settings. With a favorable safety profile, TAGRISSO plus chemotherapy offers the potential to extend patient survival while maintaining life quality during treatment.
Even with longer follow-up, the combination's safety profile remains consistent with established individual drug profiles, despite higher adverse event rates primarily due to chemotherapy-related effects. The discontinuation of treatment due to adverse effects was low across both trial arms.
TAGRISSO plus chemotherapy has received approval in more than 80 countries, including major markets such as the US, EU, China, and Japan, marking a significant advancement in the global fight against EGFRm NSCLC.
